US House Member Has Questions On FDA’s Policy On NMN, Also Asks For Public Hearing

Because FDA “suddenly changed its position and advised companies of its determination that NMN is excluded from the definition of a dietary supplement,” Rep. Jeff Duncan states, a public hearing “would be incredibly beneficial as the dietary supplement industry seeks clarity on the FDA’s actions.”

• Source: Shutterstock

Six weeks after US dietary supplement industry trade groups petition the Food and Drug Administration to allow the use of beta-nicotinamide mononucleotide as a dietary ingredient, an industry ally in the House asks the agency to conduct a public hearing on the question.

More from Regulation

More from Policy & Regulation